| Issue Date | Title | Author(s) |
| 1 | 2014 | Altered vasoactive peptide composition in the tissues of Cathepsin A deficient mice | Timur, Zehra; Akyıldız Demir, Seçil; Çalhan, Y.; Korak, Tuğcan; Ateş, Edanur; Seyrantepe, Volkan |
| 2 | 2014 | Comparison of ishage-based CD34 (+) cell enumeration protocols on BD facs canto ıı and attune flow cytometers | Kozanoğlu, İlknur; Ünver, Gülşah; Sarıtürk, Çağla; Baran, Yusuf ; Yeral, Mahmut; Boğa, Can; Özdoğu, Hakan |
| 3 | 2014 | Cytotoxic and apoptotic effects of fisetin, hesperetin and vitexinon acute promyelocytic leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 4 | 2014 | Cytotoxic and cytostatic effects of ponatinib on imatinib-sensitive and-resistant chronic myeloid leukemia cells | Yandım, Melis Kartal; Baran, Yusuf |
| 5 | 2014 | Effects of hesperidin on non-small cell lung cancer cells | Bireller, Elif Sinem; Cincin, Zeynep Birsu; Ünlü, Miray ; Kıran, Bayram; Baran, Yusuf ; Çakmakoğlu, Bedia |
| 6 | 2014 | Expression levels of ceramide-generating and clearance genes in newly diagnosed and tyrosine kinase inhibitor-resistant chronic myeloid leukemia patients: An attempt to find novel targets | Kartal Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, Özden; Özcan, Mehmet Ali; Saydam, Güray; Baran, Yusuf |
| 7 | 2014 | Expression levels of ceramide-metabolising genes in newly diagnosed and tyrosine kinase inhibitor-resistant chronic myeloid leukemia (CML) patients: The discovery of novel targets in CML | Yandım, Melis Kartal; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, O.; Özcan, Mehmet Ali; Saydam, Göksel; Baran, Yusuf |
| 8 | 2014 | Inhibition of jumonji C domain containing histone demethylases in acute myeloid leukemia | Hastar, N.; Koca, D.; Baran, Yusuf |
| 9 | 2014 | Investigation of effects of fisetin, vitexin and hesperetin on chronic myeloid leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 10 | 2014 | JAK/STAT Signalling pathway genes in the regulation of tyrosine kinase inhibitors induced and clinical process in chronic myeloid leukemia patients | Kiraz, Yağmur ; Kartal Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, I.; Özcan, Mehmet Ali; Saydam, Göksel; Şahin, Fahri; Avcu, Ferit; Ural, Ali Uğur; Ünal, Ali; Baran, Yusuf |
| 11 | 2014 | Mass spectrometry and thin layer chromatography analysis of brain gangliosides in Tay-Sachs disease mouse models | Seyrantepe, Volkan ; Timur, Zehra; Marsching, C.; Sandhoff, Roger |
| 12 | 2014 | A novel biomarker for drug resistance in chronic myeloid leukemia: MicroRNA-17 | Baran, Yusuf ; Fıratlıgil, Burcu ; Kartal Yandım, Melis; Kiraz, Yağmur ; Kozanoğlu, İlknur; Özdoğu, Hakan; Ünal, Ali |
| 13 | 2014 | Silver and zinc oxide based nano powders and their polymer based nanocomposites for antibacterial application | Abatay, Ezgi; Özmen, Tuğçe; Arslanoğlu, Alper ; Tanoğlu, Metin |
| 14 | 2014 | Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis | Tezcanlı Kaymaz, Burçin; Selvi, Nur; Adan Gökbulut, Aysun ; Aktan, Çağdaş; Gündüz, Cumhur; Saydam, Güray; Baran, Yusuf ; Kosova, Buket |
| 15 | 2014 | Targeting sphingosine kinase-1/spingosine-1-phosphate receptor 2 signalling pathway to overcome T315I mutation in 32DCL3 cells | Adan Gökbulut, Aysun ; Öğretmen, Besim; Baran, Yusuf |
| 16 | 2014 | Therapeutic potential of fisetin, vitexin and hesperetin on chronic myeloid leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
